Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Debt (2022 - 2025)

Historic Total Debt for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $50.9 million.

  • Taysha Gene Therapies' Total Debt rose 1834.03% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 1834.03%. This contributed to the annual value of $43.9 million for FY2024, which is 847.73% up from last year.
  • Taysha Gene Therapies' Total Debt amounted to $50.9 million in Q3 2025, which was up 1834.03% from $41.1 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Total Debt peaked at $179.1 million during Q3 2023, and registered a low of $37.4 million during Q1 2022.
  • Over the past 4 years, Taysha Gene Therapies' median Total Debt value was $40.5 million (recorded in 2023), while the average stood at $49.8 million.
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 37410.05% in 2023, then crashed by 7600.48% in 2024.
  • Taysha Gene Therapies' Total Debt (Quarter) stood at $38.0 million in 2022, then increased by 6.69% to $40.5 million in 2023, then increased by 8.48% to $43.9 million in 2024, then grew by 15.73% to $50.9 million in 2025.
  • Its last three reported values are $50.9 million in Q3 2025, $41.1 million for Q2 2025, and $42.5 million during Q1 2025.